221 related articles for article (PubMed ID: 24791250)
1. Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer.
Srivastava MK; Zhu L; Harris-White M; Huang M; St John M; Lee JM; Salgia R; Cameron RB; Strieter R; Dubinett S; Sharma S
Immunotargets Ther; 2012 Oct; 2012(1):7-12. PubMed ID: 24791250
[TBL] [Abstract][Full Text] [Related]
2. Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
Srivastava MK; Zhu L; Harris-White M; Kar UK; Huang M; Johnson MF; Lee JM; Elashoff D; Strieter R; Dubinett S; Sharma S
PLoS One; 2012; 7(7):e40677. PubMed ID: 22815789
[TBL] [Abstract][Full Text] [Related]
3. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
5. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
6. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
7. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
[TBL] [Abstract][Full Text] [Related]
9. Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.
Albeituni SH; Ding C; Yan J
Cancer J; 2013; 19(6):490-501. PubMed ID: 24270348
[TBL] [Abstract][Full Text] [Related]
10. Targeting Myeloid-Derived Suppressor Cells in Cancer.
Anani W; Shurin MR
Adv Exp Med Biol; 2017; 1036():105-128. PubMed ID: 29275468
[TBL] [Abstract][Full Text] [Related]
11. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.
Wilkerson A; Kim J; Huang AY; Zhang M
Curr Top Med Chem; 2017; 17(16):1843-1857. PubMed ID: 27875974
[TBL] [Abstract][Full Text] [Related]
13. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.
Draghiciu O; Lubbers J; Nijman HW; Daemen T
Oncoimmunology; 2015 Jan; 4(1):e954829. PubMed ID: 25949858
[TBL] [Abstract][Full Text] [Related]
14. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells.
Lim J; Lee A; Lee HG; Lim JS
Biomol Ther (Seoul); 2020 Jan; 28(1):1-17. PubMed ID: 31431006
[TBL] [Abstract][Full Text] [Related]
16. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets.
Al-Mterin MA; Elkord E
Explor Target Antitumor Ther; 2022; 3(4):497-510. PubMed ID: 36081407
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-Derived Suppressor Cells in
Fresno M; Gironès N
Front Cell Infect Microbiol; 2021; 11():737364. PubMed ID: 34513737
[TBL] [Abstract][Full Text] [Related]
19. Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers.
Lim HX; Kim TS; Poh CL
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443699
[TBL] [Abstract][Full Text] [Related]
20. STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.
Safarzadeh E; Mohammadi A; Mansoori B; Duijf PHG; Hashemzadeh S; Khaze V; Kazemi T; Derakhshani A; Silvestris N; Baradaran B
Front Immunol; 2020; 11():613215. PubMed ID: 33679700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
